fda glp-1 compounding crackdown news october 2025 Troubling Findings in Study of Compounders fda compounding semaglutide crackdown news

PMID 37531876

While individual results vary, many patients begin to notice changes within the first few weeks

out-of-pocket payments for the same medication carry no tax benefit, making FSA and HSA strategies substantially more cost-effective for insured and self-employed patients alike

Primary Care Practitioners/Specialists (e.g., family physicians, nurse practitioners, gastroenterologists, endocrinologists, bariatric specialists, surgeons, endoscopists, dentists) Share the risk of aspiration associated with delayed gastric emptying and provide information about fasting and holding of the medication for all patients who are taking GLP-1 receptor agonists and undergoing procedures or imaging for which anesthesia is required

Hims & Hers, a publicly traded company, is perhaps the most prominent marketer of compounded weight-loss drugs, having placed Super Bowl ads in 2025 and 2026